This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demaria, S. Articles by Formenti, S. C. Search for Related Content PubMed PubMed Citation Articles by Demaria, S. Articles by Formenti, S. C.

Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer

Departments of ¹ Pathology, ² Radiation Oncology, and ³ Radiology, New York University School of Medicine, New York, New York; and ⁴ Howard Hughes Medical Institute, University of California at Berkeley, Berkeley, California

Requests for reprints: Sandra Demaria, Department of Pathology, MSB-563, New York University School of Medicine, 550 First Avenue, New York, NY 10016. Phone: 212-263-7308; Fax: 212-263-8211; E-mail: demars01{at}med.nyu.edu.

Purpose: Ionizing radiation therapy (RT) is an important component in the management of breast cancer. Although the primary tumor can be successfully treated by surgery and RT, metastatic breast cancer remains a therapeutic challenge. Here we tested the hypothesis that the combination of RT to the primary tumor with CTLA-4 blockade can elicit antitumor immunity inhibiting the metastases.

Experimental Design: The poorly immunogenic metastatic mouse mammary carcinoma 4T1 was used as a model. Mice were injected s.c. with 4T1 cells, and treatment was started 13 days later when the primary tumors measured 5 mm in average diameter. Mice were randomly assigned to four treatment groups receiving: (1) control IgG (IgG), (2) RT + IgG, (3) 9H10 monoclonal antibody against CTLA-4, (4) RT + 9H10. RT was delivered to the primary tumor by one or two fractions of 12 Gy. 9H10 and IgG were given i.p. thrice after RT.

Results: Consistent with the fact that 4T1 is poorly immunogenic, 9H10 alone did not have any effect on primary tumor growth or survival. RT was able to delay the growth of the primary irradiated tumor, but in the absence of 9H10 survival was similar to that of control mice. In contrast, mice treated with RT + 9H10 had a statistically significant survival advantage. The increased survival correlated with inhibition of lung metastases formation and required CD8+ but not CD4+ T cells.

Conclusions: The combination of local RT with CTLA-4 blockade is a promising new immunotherapeutic strategy against poorly immunogenic metastatic cancers.

Key Words: Immunotherapy • CD8+ T cells • ionizing radiation • CTLA-4 receptor

This article has been cited by other articles:

				K. A. Pilones, N. Kawashima, A. M. Yang, J. S. Babb, S. C. Formenti, and S. Demaria Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade Clin. Cancer Res., January 15, 2009; 15(2): 597 - 606. [Abstract] [Full Text] [PDF]

				L. Fong and E. J. Small Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment J. Clin. Oncol., November 10, 2008; 26(32): 5275 - 5283. [Abstract] [Full Text] [PDF]

				J. D. Wolchok and Y. Saenger The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation Oncologist, October 1, 2008; 13(suppl_4): 2 - 9. [Abstract] [Full Text] [PDF]

				S. Matsumura, B. Wang, N. Kawashima, S. Braunstein, M. Badura, T. O. Cameron, J. S. Babb, R. J. Schneider, S. C. Formenti, M. L. Dustin, et al. Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells J. Immunol., September 1, 2008; 181(5): 3099 - 3107. [Abstract] [Full Text] [PDF]

				S. C. Formenti and S. Demaria Effects of Chemoradiation on Tumor-Host Interactions: The Immunologic Side J. Clin. Oncol., March 20, 2008; 26(9): 1562 - 1563. [Full Text] [PDF]

				H. L. Kaufman and C. R. Divgi Optimizing Prostate Cancer Treatment by Combining Local Radiation Therapy with Systemic Vaccination Clin. Cancer Res., October 1, 2005; 11(19): 6757 - 6762. [Full Text] [PDF]